Trial Profile
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Sozinibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Opthea
- 19 Mar 2024 According to an Opthea media release, will host a virtual key opinion leader (KOL) event on Wednesday, April 3, 2024, from 10:00 to 11:30 am ET, featuring presentations from global retina experts including the Phase 2b data demonstrating superiority in combination with standard-of-care therapy.
- 01 Jun 2023 Results assessing safety and efficacy of OPT-302 in combination with ranibizumab published in the Ophthalmology.
- 13 Feb 2023 According to Opthea media release, the results from this study has been published in the journal of the American Academy of Ophthalmology. The published research article in ophthalmology titled is available as "A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration" can be accessed under "Articles in Press" at: https://www.aaojournal.org/article/S0161-6420(23)00066-0/fulltext."